Rpg Life Sciences Limited · NSE:RPGLIFE
Rpg Life Sciences — 9M FY2023 Earnings Presentation
29 slides from Rpg Life Sciences's earnings presentation
Slide 1: Investors' Presentation 9M FY23
Investors’ Presentation 9M FY23
Slide 2: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 3: RPG Life Sciences Overview
RPG Life Sciences Overview RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Leader in Immunosuppressants Domestic Formulations
Slide 4: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio Key Therapies Key Products Existing Portfolio New Portfolio Immunosuppressants Text Book Brands Specialty Chronic Life Cycle Management Portfolio (Existing Products) • Nephrology Trastuzumab Vildagliptin • Rheumatology Azathioprine • Oncology Azathioprine Adalimum
Slide 5: Key Financials, Business Highlights & Strategy
Key Financials, Business Highlights & Strategy 5
Slide 6: Key Highlights of 9M FY23
Key Highlights of 9M FY23 RPGLS continues to grow faster than the market at 19%* vs 6.5% (IPM)** PBT continues to grow healthy double digit (+25%) despite inflationary pressures and rising costs due to geo-political situations Profit margins’ upward trajectory continues – EBITDA margin reaches recor
Slide 7: Company Financial Performance – Profit Margins
Company Financial Performance – Profit Margins Upward y-o-y Record setting Trajectory continues – EBITDA Margin reaches 22.8% & PBT Margin 19.7% EBITDA% 22.8% 20% PBT% 18% 19.7% 17% 16% 14% 12% 11% 10% 10% 10% 9% 8% 6% 6% 5% 4% 4% 4% 4% 1% 0% 0% 7
Slide 8: Key Financials: 9M FY23
Key Financials: 9M FY23 (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 394.3 336.4 89.7 77.9 74.6 62.2 22.8% 19.7% 22.2% 18.5% 9M FY22 9M FY23 9M FY22 9M FY23 9M FY22 9M FY23 PAT & PAT Margin EPS 57.3 34.6 44.0 26.6 14.5% 13.1% 9M FY22 9
Slide 9: Key Financials' Trends
Key Financials’ Trends (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 440.2 89.4 89.7 375.6 389.1 394.3 70.8 73.2 77.9 330.2 59.9 53.6 34.4 41.8 15.1 10.4% 15.9% 18.2% 20.3% 22.8% 11.1% 13.8% 16.6% 4.6% 19.7% FY19 FY20 FY21 FY22 9M FY23
Slide 10: Key Financials' Trends: Company continues to remain Debt-free
Key Financials’ Trends ROCE% ROE% Debt/Equity Ratio 27.9% 0.22 23.6% 24.3% 18.5% 20.1% 16.4% 11.0% 6.7% 0.06 0.01 0.00 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Company continues to remain Debt-free 10
Slide 11: Business Segment-wise Performance: 9M FY23
Business Segment-wise Performance: 9M FY23 Sales (Rs Crs) • Domestic Formulations contributed 65% to total sales of 9M FY23 Domestic • 19% sales growth majorly driven by legacy products • Better than market growth 254.1 Formulations 214.2 • New products* contribution improving consistently (currentl
Slide 12: Key Financials: Q3 FY23
Key Financials: Q3 FY23 (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 130.6 29.7 115.6 25.7 24.7 20.6 22.8% 19.7% 21.4% 17.8% Q3 FY22 Q3 FY23 Q3 FY22 Q3 FY23 Q3 FY22 Q3 FY23 PAT & PAT Margin EPS 19.1 11.6 14.6 8.8 14.6% 12.7% Q3 FY22 Q3
Slide 13: RPG Life Sciences ICRA Rating Reaffirmed in FY22
RPG Life Sciences ICRA Rating Reaffirmed in FY22 Long term rating reaffirmed at A Short term rating reaffirmed at A1 Outlook on long term rating has been retained as Stable The rating reaffirmation factors: ➢ Strong brands in the Indian Pharmaceutical Industry ➢ Considerable improvement in the opera
Slide 14: Domestic Formulations (DF)
Domestic Formulations (DF) • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in Immunosuppressant category • Good Customer Coverage - Cardiol
Slide 15: International Formulations (IF)
International Formulations (IF) • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and business relationship with some of the
Slide 16: APIs
APIs • High value, low volume, niche APIs • Mature stable molecules • Provides backward integration to International Formulations business • Footprints across geographies - LATAM, Iran, Germany, China, South Korea, Bangladesh, Egypt, India, etc. • Strong customer focus - long lasting relationship wi
Slide 17: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities 17
Slide 18: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved Formulations Unit 2, Ankleshwar • F2 unit caters
Slide 19: Strong Backend Capabilities
Strong Backend Capabilities Quality Regulatory • All critical SOPs harmonized through CQA • Well established & evolved Regulatory function catering • Quarterly internal audit of all plants by CQA to Canada, UK, EU, Australia and emerging markets • All critical deviations, change controls and market
Slide 20: Operational Highlights
Operational Highlights £ An FPG Company RPG UIE SCIENCES
Slide 21: Digitalization Initiatives to Transform Business
Digitalization Initiatives to Transform Business Game Changer Customer Connect Initiative Employee Connect Initiatives Digital Platform for comprehensive Salesforce Operations tracking: #Customer visits, customer engagement activities, sales performance analytics etc Anytime, Anywhere Doctor Support
Slide 22: People Initiatives to build Performance Culture with focus on Happiness
People Initiatives to build Performance Culture with focus on Happiness I Feel Connected Authentic Relationship with Manager/s, Trust amongst Peers, Good Team Chemistry, I Live a Purposeful & Camaraderie at Work, Respect for Others’ I cherish our Culture Capabilities, Constructive Conflict Managemen
Slide 23: Initiatives for building a Performance Driven Culture: Glimpses (9M FY23)
Initiatives for building a Performance Driven Culture: Glimpses (9M FY23) Skilling Rewards & Recognition Employee engagement: Parivar Tyohar Utsav Employee Connect Idea Generation
Slide 24: FY23 Priorities
FY23 Priorities Maintain growth momentum in top-line and bottom-line across the business segments Continue to grow our presence in chronic and specialty therapies in DF through new product launches and new customer segments Continue to build iconic/legacy brands into strategic assets Continue to enh
Slide 25: Awards & Recognitions
Awards & Recognitions £ An FPG Company PG IF SCIENCES
Slide 26: RPG Life Sciences Awarded with 'Jamnalal Bajaj Award for Fair Business Practices'
RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’ Jamnalal Bajaj Award for Fair Business Practices (2021-22)
Slide 27: RPG Life Sciences Bagged Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA Industry Recognition to RPG Life Sciences Best Patent Award Best Corporate Citizen Award
Slide 28: RPG Life Sciences is one of India's Best Workplaces in 2020
RPG Life Sciences is one of India’s Best Workplace in 2020 – Amongst Top 100 • Ranked 85 amongst India's 100 Best Companies to Work For 2020 • One of India's Best Workplaces in Biotechnology & Pharmaceuticals by Great Place to Work® Institute 28
Slide 29: An RPG Company RPG Life Sciences
00006 000 Zz An FPG Company RPG LIFE SCIENCES